Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 44Gastrointestinal 44Thoracic 38Genitourinary 29Lymphoid 26CNS 20Dermatologic 19Breast 18Sarcoma 17Head & Neck 15Other hematologic neoplasm 11Plasma cell 5Myeloid 5Endocrine 5Tumor-Agnostic 3Other solid neoplasm 2NET 2Classical hematology 1

Conditions

Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Mesothelioma, Malignant 1Cervical Adenocarcinoma 1Carcinoma, Neuroendocrine 1Carcinoma, Merkel Cell 1Adenoma, Islet Cell 1Adenocarcinoma, Mucinous 1

Interventions

Cisplatin 145pembrolizumab 129Carboplatin 124Injections 108Pemetrexed 97Paclitaxel 97Gemcitabine 85Irinotecan 75Nivolumab 71Cyclophosphamide 71Docetaxel 68Bevacizumab 57Oxaliplatin 49Fluorouracil 48atezolizumab 46Capecitabine 46Etoposide 42Leucovorin 41tislelizumab 40toripalimab 36fludarabine 32Ipilimumab 30Drug Therapy 30Topotecan 29durvalumab 28Vincristine 27Early Intervention, Educational 27Radiotherapy 26Interviews as Topic 25Filgrastim 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Disulfides × Other solid neoplasm × Clear all
NCT03074513 2026-03-11

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
133 enrolled
DermatologicEndocrineHead & NeckOther solid neoplasmThoracic

Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Adenocarcinoma, Mucinous, Adenoma, Islet Cell, Nasopharyngeal Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Neuroendocrine

NCT02020707 2024-07-26

Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

Mayo Clinic

Phase 1 Completed
43 enrolled
DermatologicGenitourinaryGynecologicOther solid neoplasmSarcoma

Cervical Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡